Latest Breaking News On - Katja margell - Page 2 : comparemela.com

Hansa Biopharma announces $70 million non-dilutive product finance transaction with NovaQuest to support continued development of the company s antibody-cleaving enzyme technology platform

Proceeds will be mainly utilized to: - Further strengthen the Company s position in kidney transplantation through the continued support of ongoing European.

Hansa biopharmaPhilip nunesPrnewswire hansa biopharmaKlaus sindahlBrett fleshmanDonato spotaKatja margellDrug administrationBackbay communicationsHead of corporate communicationsBiologics license applicationNasdaq stockholmNovaquest capital managementChief financial officerManaging directorProduct finance

Hansa Biopharma announces first patient treated in the post-authorization efficacy study (PAES) of Idefirix® (imlifidase) in highly sensitized kidney transplant patients

/PRNewswire/ Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), pioneer in enzyme technology for rare immunological conditions, announces today that the.

Comunidad autonoma de catalunaHansa biopharmaVincenza nigroKlaus sindahlOriol bestardKatja margellChristian kjellmanEuropean unionHebron university hospitalEuropean medicines agencyEuropean medicines agency ema priorityHead of corporate communicationsNasdaq stockholmKidney transplantationChief scientific officerKidney transplant franchise lead

Bulletin from the Annual General Meeting in Hansa Biopharma AB (publ)

/PRNewswire/ Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), pioneer in enzyme technology for rare immunological conditions, has today on June 30,.

United statesHansa biopharmaAndreas eggertKlaus sindahlEva nilsagAnders gersel pedersenHilary malonePrnewswire hansa biopharmaPeter nicklinKatja margellShare rights programAudit committeeRemuneration committeeHansa biopharma option programNomination committeeExchange commission

NICE recommends use of Hansa Biopharma s Idefirix® (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients

NICE recommends use of Hansa Biopharma s Idefirix® (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomNorthern irelandAdnan sharifHansa biopharmaPrnewswire hansa biopharmaKlaus sindahlKatja margellNational institute for healthEuropean unionEuropean commissionEuropean medicines agencyEuropean medicines agency ema priorityKidney research united kingdomRegulatory agencyNasdaq stockholmNational institute

The Nomination Committee in Hansa Biopharma proposes Peter Nicklin as new chair of the Board of Directors at the Annual General Meeting 2022

/PRNewswire/ Hansa Biopharma AB, "Hansa", (Nasdaq Stockholm: HNSA), pioneer in enzyme technology for rare immunological conditions, today announces that.

United statesHansa biopharmaPrnewswire hansa biopharmaKlaus sindahlPeter nicklinUlf wiinbergJannis kitsakisKatja margellNomination committeeNomination committee in hansa biopharmaHead of corporate communicationsAnnual general meetingNasdaq stockholmAnnual generalCorporate communicationsHansa biopharma ab